Penn Capital Management
ANIP icon

Penn Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Penn Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.5M Buy
213,246
+5,884
+3% +$453K 1.13% 45
2026
Q2 		$17.2M Buy
207,362
+27,646
+15% +$2.22M 1.09% 43
2026
Q1 		$13.8M Buy
179,716
+42,322
+31% +$3.3M 1.07% 53
2025
Q4 		$10.9M Buy
137,394
+131,030
+2,059% +$11.3M 0.87% 66
2025
Q3 		$583K Buy
6,364
+387
+6% +$31.6K 0.04% 140
2025
Q2 		$390K Sell
5,977
-719
-11% -$46.8K 0.03% 138
2025
Q1 		$448K Buy
+6,696
New +$400K 0.04% 129
2014
Q4 		– Sell
-143,220
Closed -$4.05M – 295
2014
Q3 		$4.05M Sell
143,220
-110
-0.1% -$3.3K 0.17% 166
2014
Q2 		$4.94M Buy
143,330
+25,086
+21% +$787K 0.19% 150
2014
Q1 		$3.71M Buy
+118,244
New +$3.14M 0.14% 168

Other funds holding ANIP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Mizuho Markets Americas
Mizuho Markets Americas New York $6.82B AUM 29.92% 1-Year Est. Return

Penn Capital Management's ANIP Position: Q3 2026 in Review

Penn Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 2.8% in Q3 2026, buying an estimated $453K and bringing the position to 213,246 shares worth $15.5M. The position accounts for 1.13% of the portfolio, ranked #45.

Penn Capital Management first reported a position in ANIP in Q1 2014 and has held it in 10 quarters since. The position peaked at $17.2M in Q2 2026. 147 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Penn Capital Management held 213,246 shares of ANI Pharmaceuticals worth $15.5M as of Q3 2026.
  • Penn Capital Management bought 5,884 ANI Pharmaceuticals shares in Q3 2026, an estimated $453K.
  • ANI Pharmaceuticals made up 1.13% of Penn Capital Management's portfolio in Q3 2026, its #45 holding.
  • Penn Capital Management first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 10 quarters since.
  • Penn Capital Management's ANI Pharmaceuticals position peaked at $17.2M in Q2 2026.
  • 147 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Penn Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.